Millipore Sigma Vibrant Logo

06-758 Anti-acetyl-p53 Antibody (Lys373, Lys382)

View Products on Sigmaaldrich.com
06-758
200 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      VrtWBRbSerumPolyclonal Antibody
      Description
      Catalogue Number06-758
      Replaces04-1137
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-acetyl-p53 Antibody (Lys373, Lys382)
      Background Informationp53 is a DNA-binding, oligomerization domain and transcription activation domain-containing tumor suppressor that upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation and cell cycle control mechanisms. p53 localizes to the nucleus yet can be chaperoned to the cytoplasm by the negative regulator MDM2, an E3 ubiquitin ligase that is upregulated in the presence of active p53, where MDM2 polyubiquitinates p53 for proteasome targeting. p53 can assemble into tetramers in the absence of DNA, fluctuates between latent and active (DNA-binding) conformations, and is differentially activated through posttranslational modifications including phosphorylation and acetylation. Mutations in the DNA-binding domain (DBD) (amino acids 110-286) of p53 can compromise energetically favorable association with cis elements and are implicated in several human cancers.
      References
      Product Information
      FormatSerum
      Control
      • Breast Cancer, Colon, Skin tissue
      PresentationRabbit polyclonal antiserum containing 0.05% sodium azide. Frozen solution.
      Quality LevelMQ100
      Applications
      ApplicationDetect acetyl-p53 (Lys373) with Anti-acetyl-p53 Antibody (Lys373, Lys382) (Rabbit Polyclonal Antibody), that has been shown to work in WB.
      Key Applications
      • Western Blotting
      Application NotesWestern Blot (on recombinant protein only)
      Biological Information
      Immunogenpeptide of human p53 corresponding to amino acids 368-389 with a duplication of amino acids 376 and 377 (HLKSKACKGQSTSTSRHKACKLMFKTC) where ACK denotes acetyl-lysine
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRabbit
      SpecificityRecognizes p53 acetylated in vitro by recombinant p300, and for peptide containing acetyl-lysine 373 but not for the peptide containing acetyl-lysine 320.
      IsotypeIgG
      Species Reactivity
      • Vertebrates
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryTumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing DNA-binding, oligomerization and transcription activation domains. It is postulated to bind as a tetramer to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome.
      Gene Symbol
      • TP53
      • P53
      • TRP53
      • p53
      • LFS1
      Modifications
      • Acetylation
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P04637 # Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression.
      COFACTOR: Binds 1 zinc ion per subunit.
      SIZE: 393 amino acids; 43653 Da
      SUBUNIT: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer- associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. C- terminus interacts with TAF1, when TAF1 is part of the TFIID complex. Interacts with ING4 and this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and P53DINP1. Interacts with WWOX. May interacts with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1 (By similarity). Interacts with BANP.
      SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization.
      DOMAIN: SwissProt: P04637 The nuclear export signal acts as a transcriptional repression domain.
      PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence. & Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylated on Thr-18 by VRK1, which may prevent the interaction with MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. & Dephosphorylated by PP2A. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A. & May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line. & Ubiquitinated by SYVN1, which leads to proteasomal degradation.
      DISEASE: SwissProt: P04637 # TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. & Defects in TP53 are involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239]. ESCC is a tumor of the esophagus. & Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of both a proband with a sarcoma and two other first-degree relatives with a cancer by age 45 years. In these families the affected relatives develop a diverse set of malignancies at unusually early ages. The spectrum of cancers in LFS includes breast carcinomas, soft-tissue sarcomas, brain tumors, osteosarcoma, leukemia and adreno-cortical carcinoma. Other possible component tumors of LFS are melanoma, gonadal cell tumors and carcinomas of the lung, pancreas and prostate. & Defects in TP53 may be associated with nasopharyngeal carcinoma [MIM:161550]; also known as nasopharyngeal cancer. & Defects in TP53 are found in Barrett metaplasia; also known as Barrett esophagus. It is a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma. & Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]. & Defects in TP53 are involved in oral squamous cell carcinoma (OSCC). Cigarette smoke is a prime mutagenic agent in cancer of the aerodigestive tract. & Defects in TP53 are a cause of lung cancer [MIM:211980]. & Defects in TP53 are a cause of choroid plexus papilloma [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood. & Defects in TP53 are a cause of one form of hereditary adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor, representing about 0.4% of childhood tumors, with a high incidence of associated tumors. ADCC occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome [MIM:130650] and is a component tumor in Li-Fraumeni syndrome [MIM:151623].
      SIMILARITY: Belongs to the p53 family.
      Molecular Weight53 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by an in vitro acetyl transferase assay on recombinant p300, HAT domain (Catalog #14-418)
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size200 µL
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Anti-acetyl-p53 Antibody (Lys373, Lys382) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-acetyl-p53 Antibody (Lys373, Lys382) Certificates of Analysis

      TitleLot Number
      Anti-acetyl-p53 (Lys373, Lys382) (rabbit antiserum) 2971826
      Anti-acetyl-p53 (Lys373, Lys382) (rabbit antiserum) 2853550
      Anti-acetyl-p53 (Lys373, Lys382) (rabbit antiserum) 2934478
      Anti-acetyl-p53 (Lys373, Lys382) - 17115 17115
      Anti-acetyl-p53 (Lys373, Lys382) - 22561 22561
      Anti-acetyl-p53 (Lys373, Lys382) - 27557 27557
      Anti-acetyl-p53 (Lys373, Lys382) - 29494 29494
      Anti-acetyl-p53 (Lys373, Lys382) - 3149832 3149832
      Anti-acetyl-p53 (Lys373, Lys382) - 3286050 3286050
      Anti-acetyl-p53 (Lys373, Lys382) - 3760541 3760541

      References

      Reference overviewApplicationPub Med ID
      Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells.
      Diss, E; Nalabothula, N; Nguyen, D; Chang, E; Kwok, Y; Carrier, F
      Journal of clinical oncology and research  2  2014

      Show Abstract
      25379568 25379568
      Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G⁹³A ALS mice: overlapping effects or limited therapeutic opportunity?
      Mancuso, R; Del Valle, J; Morell, M; Pallás, M; Osta, R; Navarro, X
      Orphanet journal of rare diseases  9  78  2014

      Show Abstract
      Western Blotting24885036 24885036
      Exercise Increases Markers of Spermatogenesis in Rats Selectively Bred for Low Running Capacity.
      Torma, F; Koltai, E; Nagy, E; Ziaaldini, MM; Posa, A; Koch, LG; Britton, SL; Boldogh, I; Radak, Z
      PloS one  9  e114075  2014

      Show Abstract
      Western Blotting25493948 25493948
      Quantitative proteomic characterization of ethanol-responsive pathways in rat microglial cells.
      Bell-Temin, Harris, et al.
      J. Proteome Res., 12: 2067-77 (2013)  2013

      Show Abstract
      23495833 23495833
      ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage.
      Liu, N; Wang, J; Wang, J; Wang, R; Liu, Z; Yu, Y; Lu, H
      Cancer research  73  3749-60  2013

      Show Abstract
      23576563 23576563
      Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
      Chithra D Palani,James F Beck,Jürgen Sonnemann
      Investigational new drugs  30  2012

      Show Abstract
      20680659 20680659
      Orphan nuclear receptor PNR/NR2E3 stimulates p53 functions by enhancing p53 acetylation.
      Wen, Z; Pyeon, D; Wang, Y; Lambert, P; Xu, W; Ahlquist, P
      Molecular and cellular biology  32  26-35  2012

      Show Abstract
      Western Blotting22025681 22025681
      Mechanisms of p53 activation and physiological relevance in the developing kidney.
      Aboudehen, K; Hilliard, S; Saifudeen, Z; El-Dahr, SS
      Am J Physiol Renal Physiol  302  F928-40  2012

      Show Abstract
      Western Blotting22237799 22237799
      Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging.
      Li, X; Khanna, A; Li, N; Wang, E
      Aging  3  985-1002  2011

      Show Abstract
      22064828 22064828
      Identification of DBC1 as a transcriptional repressor for BRCA1.
      Hiraike, H; Wada-Hiraike, O; Nakagawa, S; Koyama, S; Miyamoto, Y; Sone, K; Tanikawa, M; Tsuruga, T; Nagasaka, K; Matsumoto, Y; Oda, K; Shoji, K; Fukuhara, H; Saji, S; Nakagawa, K; Kato, S; Yano, T; Taketani, Y
      British journal of cancer  102  1061-7  2010

      Show Abstract Full Text Article
      20160719 20160719

      Related Products & Applications

      Related Products

      Catalog Number Description  
      05-224 Anti-p53 Antibody, clone BP53-12 Show Pricing & Availability
      06-1283 Anti-acetyl-p53 (Lys320) Antibody Show Pricing & Availability
      06-916 Anti-acetyl-p53 (Lys373) Antibody Show Pricing & Availability
      17-613 ChIPAb+ p53 - ChIP Validated Antibody and Primer Set Show Pricing & Availability
      AB9985 Anti-glutathione p53 (Cys141) Antibody Show Pricing & Availability
      ABE286 Anti-acetyl-p53 (Lys120) Antibody Show Pricing & Availability
      CBL404 Anti-p53 Antibody, aa 211-220, clone240 Show Pricing & Availability
      MABE199 Anti-phospho-p53 (Ser33) Antibody, clone EP2393Y, rabbit monoclonal Show Pricing & Availability
      MABE327 Anti-p53 (pantropic) Antibody, clone DO-1 Show Pricing & Availability
      MABE518 Anti-phospho-p53 (Thr377), clone EPR5678, Rabbit Monoclonal Antibody Show Pricing & Availability

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies